BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Urso L, Castello A, Rocca GC, Lancia F, Panareo S, Cittanti C, Uccelli L, Florimonte L, Castellani M, Ippolito C, Frassoldati A, Bartolomei M. Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol 2022. [PMID: 35217902 DOI: 10.1007/s00432-022-03958-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gaudreault M, Chang D, Hardcastle N, McIntosh L, Jackson P, Kron T, Udovicich C, Hofman MS, Siva S. Feasibility of biology-guided radiotherapy for metastatic renal cell carcinoma driven by PSMA PET imaging. Clin Transl Radiat Oncol 2023;40:100608. [PMID: 36942088 DOI: 10.1016/j.ctro.2023.100608] [Reference Citation Analysis]
2 Urso L, Rocca GC, Uccelli L, Ippolito C, Bartolomei M. 18 F-Choline Versus 68 Ga-PSMA-11 PET/CT Imaging Comparison in Incidental Clear Cell Renal Cell Carcinoma. Clin Nucl Med 2023;48:e178-80. [PMID: 36728284 DOI: 10.1097/RLU.0000000000004515] [Reference Citation Analysis]
3 Dondi F, Lazzarato A, Gorica J, Guglielmo P, Borgia F, Filice R, Vento A, Pacella S, Camedda R, Caracciolo M, De Feo MS, Mammucci P, Frantellizzi V, Ortolan N, Fiasconaro E, Urso L, Evangelista L, Laudicella R, Santo G. PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score. Life 2023;13:611. [DOI: 10.3390/life13030611] [Reference Citation Analysis]
4 Posada Calderon L, Eismann L, Reese SW, Reznik E, Hakimi AA. Advances in Imaging-Based Biomarkers in Renal Cell Carcinoma: A Critical Analysis of the Current Literature. Cancers (Basel) 2023;15. [PMID: 36672304 DOI: 10.3390/cancers15020354] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rizzo A, Racca M, Dall'Armellina S, Rescigno P, Banna GL, Albano D, Dondi F, Bertagna F, Annunziata S, Treglia G. The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers (Basel) 2023;15. [PMID: 36672305 DOI: 10.3390/cancers15020355] [Reference Citation Analysis]
6 Fan L, Xu Y, Zhao J, Tang W, Zhang Z, Zhang Y, Xue Q. The diagnostic performance of 18F-FDG PET/CT in recurrent renal cell carcinoma: a systematic review and meta-analysis. Clin Transl Imaging 2022. [DOI: 10.1007/s40336-022-00533-5] [Reference Citation Analysis]
7 Caracciolo M, Castello A, Urso L, Borgia F, Ortolan N, Uccelli L, Cittanti C, Castellani M, Bartolomei M, Lazzeri M, Lopci E. The Role of [68Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review. Cancers (Basel) 2022;14:5036. [PMID: 36291820 DOI: 10.3390/cancers14205036] [Reference Citation Analysis]
8 Rizzo A, Dall'Armellina S, Pizzuto DA, Perotti G, Zagaria L, Lanni V, Treglia G, Racca M, Annunziata S. PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor? Cancers (Basel) 2022;14:4039. [PMID: 36011032 DOI: 10.3390/cancers14164039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Urso L, Lancia F, Ortolan N, Frapoli M, Rauso M, Artioli P, Cittanti C, Uccelli L, Frassoldati A, Evangelista L, Bartolomei M. 18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? Clin Transl Imaging. [DOI: 10.1007/s40336-022-00515-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]